Skip to main content

Common Dreams. Journalism funded by people, not corporations.

There has never been—and never will be—an advertisement on our site except for this one: without readers like you supporting our work, we wouldn't exist.

No corporate influence. No pay-wall. Independent news and opinion 365 days a year that is freely available to all and funded by those who support our mission: To inform. To inspire. To ignite change for the common good.

Our mission is clear. Our model is simple. If you can, please support our Fall Campaign today.

Support Our Work -- No corporate influence. No pay-wall. Independent news funded by those who support our mission: To inform. To inspire. To ignite change for the common good. Please support our Fall Campaign today.

Merck

Medicine pills are seen with Merck logo displayed on a screen in the background on October 10, 2021. (Photo: Jakub Porzycki/NurPhoto via Getty Images)

'Entirely Unsurprising': Merck Slammed for 4,000% Markup of Taxpayer-Funded Covid Drug

"Another example of Big Pharma reaping billions from public investment into research by charging extortionate, rip-off prices for lifesaving Covid drugs."

Jake Johnson

The New Jersey-based pharmaceutical giant Merck is facing accusations of price gouging after it charged the U.S. over $700 per patient for a taxpayer-funded coronavirus treatment that, according to research, costs just $17.74 to produce.

"This is why we need to waive patents on all Covid treatments and vaccines."

Last week, Merck announced plans to request emergency federal authorization for molnupiravir after a late-stage clinical trial showed that a five-day course of the antiviral drug cut the risk of Covid-19 hospitalization or death in half in patients with mild-to-moderate cases.

The same day Merck unveiled the results of the trial and White House officials hailed the drug as another possible tool against Covid-19, the New York Times reported that "the federal government has placed advance orders for 1.7 million courses of treatment, at a price of about $700 per patient"—far more than the estimated cost of manufacturing the drug.

According to an analysis by Melissa Barber of Harvard T. H. Chan School of Public Health and Dzintars Gotham of King’s College Hospital in London, "the cost of production for molnupiravir capsules is US$1.74 per unit, or US$17.74 per five-day regimen."

"Adding an allowance for 10% profit margin and taxes in India, we arrive at an estimated sustainable generic price of US$1.96 per capsule or US$19.99 per five-day regimen," the researchers concluded.

Dean Baker, a senior economist at the Center for Economic and Policy Research, noted that the $712 price-per-course price the U.S. government is set to pay for molnupiravir amounts to a roughly 4,000% markup.

Quartz's Annalisa Merelli reported last week that with Merck expecting to produce 10 million courses of molnupiravir before the end of 2021, the company "could bring in revenue up to $7 billion."

"This would make it, in only a few weeks, one of the 10 most lucrative drugs ever," Merelli observed.

If authorized by the U.S. Food and Drug Administration, molnupiravir—which Merck developed in partnership with the Miami-based firm Ridgeback Biotherapeutics—would be the first antiviral pill approved to treat Covid-19, potentially a major breakthrough in the fight against the global pandemic.

But it's unclear how accessible the treatment will be for people in the U.S. and around the world, given its cost and Merck's monopoly control over production. Numerous countries, including Singapore and Thailand, are already racing to secure access to the drug.

"Governments must break Merck's monopolies so generic companies can expand supply and slash prices globally," said Asia Russell, executive director of Health GAP.

Heidi Chow of the Jubilee Debt Campaign decried the $700-per-patient price the U.S. government paid for molnupiravir as "another example of Big Pharma reaping billions from public investment into research by charging extortionate, rip-off prices for lifesaving Covid drugs."

"This is why we need to waive patents on all Covid treatments and vaccines," said Chow.

As The Intercept's Sharon Lerner reported Tuesday, molnupiravir was developed with the help of tens of millions of dollars in U.S. government funding.

"The Defense Threat Reduction Agency, a division of the Department of Defense, provided more than $10 million of funding in 2013 and 2015 to Emory University," from which Ridgeback licensed the drug in 2020, Lerner noted. "The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, also provided Emory with more than $19 million in additional grants."

In addition to slamming Merck for selling the drug to the U.S. at a price 40 times higher than the cost of production, public health advocates stressed the Biden administration has an obligation to ensure that the treatment is made widely available and affordable to all.

"The public funded this drug, and therefore the public has some rights, including the rights you have it available under reasonable terms," Luis Gil Abinader, a senior researcher at Knowledge Ecology International, told The Intercept.

Abinader pointed to the federal government's so-called "march in" rights under the Bayh-Dole Act. That law, enacted in 1980, allows the government to intervene and license a federally funded drug to a third party if the manufacturer fails to make the medicine "available to the public on reasonable terms." The U.S. government has never exercised its march in rights to drive down the cost of a drug.

"The pressure for march-in rights around this drug is going to be huge," Abinader said of molnupiravir. "When the Biden administration negotiates another supply agreement with Merck, they should probably leverage those rights in order to get a better price."


Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

This is the world we live in. This is the world we cover.

Because of people like you, another world is possible. There are many battles to be won, but we will battle them together—all of us. Common Dreams is not your normal news site. We don't survive on clicks. We don't want advertising dollars. We want the world to be a better place. But we can't do it alone. It doesn't work that way. We need you. If you can help today—because every gift of every size matters—please do. Without Your Support We Simply Don't Exist.

'Progressives Won't Leave Working Families Behind': Jayapal Stands Ground Against Pelosi-Biden

"We've been clear since the spring: the infrastructure bill and the Build Back Better Act pass together—and that hasn't changed."

Brett Wilkins ·


'Too Bad We Can't Tax Egos': Elon Musk Blasted for Attack on Billionaire Tax

"This country made him rich," said one critic. "He owes us."

Julia Conley ·


'Hold the Line': Progressives Push to Block Vote on Weaker Bill Without Final Text of Build Back Better

"By holding firm on keeping the Build Back Better Act and the Bipartisan Infrastructure Bill firmly linked, progressives are giving their colleagues in the Senate the space and the leverage to negotiate the strongest package possible."

Common Dreams staff ·


Will They Lie or Finally Come Clean?: Watch Fossil Fuel CEOs Testify at Historic Hearing

"Will these executives own up to their misinformation, or keep trying to hide behind lies and spin?"

Andrea Germanos ·


'Pelosi Absolutely Destroyed' Tax on Billionaires, Says Democratic Insider

"The idea that Manchin is to blame for killing the billionaires' tax is too convenient," argued a journalist who spoke with party aides about the moribund proposal.

Kenny Stancil ·

Support our work.

We are independent, non-profit, advertising-free and 100% reader supported.

Subscribe to our newsletter.

Quality journalism. Progressive values.
Direct to your inbox.

Subscribe to our Newsletter.


Common Dreams, Inc. Founded 1997. Registered 501(c3) Non-Profit | Privacy Policy
Common Dreams Logo